Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2005

Open Access 01-10-2005 | Research article

A new option for early breast cancer patients previously irradiated for Hodgkin's disease: intraoperative radiotherapy with electrons (ELIOT)

Authors: Mattia Intra, Oreste Gentilini, Paolo Veronesi, Mario Ciocca, Alberto Luini, Roberta Lazzari, Javier Soteldo, Gabriel Farante, Roberto Orecchia, Umberto Veronesi

Published in: Breast Cancer Research | Issue 5/2005

Login to get access

Abstract

Introduction

Patients who have undergone mantle radiotherapy for Hodgkin's disease (HD) are at increased risk of developing breast cancer. In such patients, breast conserving surgery (BCS) followed by breast irradiation is generally considered contraindicated owing to the high cumulative radiation dose. Mastectomy is therefore recommended as the first option treatment in these women.

Methods

Six patients affected by early breast cancer previously treated with mantle radiation for HD underwent BCS associated with full-dose intraoperative radiotherapy with electrons (ELIOT).

Results

A total dose of 21 Gy (prescribed at 90% isodose) in five cases and 17 Gy (at 100% isodose) in one case were delivered directly to the mammary gland without acute complications and with good cosmetic results. After an average of 30.8 months of follow up, no late sequelae were observed and the patients are free of disease.

Conclusion

In patients previously irradiated for HD, ELIOT can avoid repeat irradiation of the whole breast, permit BCS and decrease the number of avoidable mastectomies.
Literature
1.
Boivin JF, O'Brien K: Solid cancer risk after treatment of Hodgkin's disease. Cancer. 1988, 61: 2541-2546.CrossRefPubMed
2.
Tucker MA, Coleman CN, Cox RS: Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 1988, 318: 76-81.CrossRefPubMed
3.
Tinger A, Wasserman TH, Klein EE, Miller EA, Roberts T, Piephoff JV, Kucik NA: The incidence of breast cancer following mantle field radiation therapy as a function of dose and technique. Int J Radiat Oncol Biol Phys. 1997, 37: 865-870. 10.1016/S0360-3016(97)00026-6.CrossRefPubMed
4.
Wolden SL, Lamborn KR, Cleary SF, Tate DJ, Donaldson SS: Second cancers following pediatric Hodgkin's disease. J Clin Oncol. 1998, 16: 536-544.CrossRefPubMed
5.
American College of Radiotherapy, American College of Surgeons, College of American Pathologists, Society of Surgical Oncology, Winchester DP, Cox JD: Standards for breast-conservation treatment. CA Cancer J Clin. 1992, 42: 134-162.CrossRef
6.
Wolden SL, Hancock SL, Carlson RW, Goffinet DR, Jeffrey SS, Hoppe RT: Management of breast cancer after Hodgkin's disease. J Clin Oncol. 2000, 18: 765-772.CrossRefPubMed
7.
Krishnan L, Jewell WR, Tawfik OW, Krishnan EC: Breast conservation therapy with tumor bed irradiation alone in a selected group of patients with stage I breast cancer. Breast J. 2001, 7: 91-96. 10.1046/j.1524-4741.2001.007002091.x.CrossRefPubMed
8.
Perera F, Engel J, Holliday R, Scott L, Girotti M, Girvan D, Chisela F, Venkatesan V: Local resection and brachytherapy confined to the lumpectomy site for early breast cancer: a pilot study. J Surg Oncol. 1997, 65: 263-267. 10.1002/(SICI)1096-9098(199708)65:4<263::AID-JSO7>3.0.CO;2-3.CrossRefPubMed
9.
Baglan KL, Martinez AA, Frazier RC, Kini VR, Kestin LL, Chen PY, Edmundson G, Mele E, Jaffray D, Vicini FA: The use of high-dose-rate brachytherapy alone after lumpectomy in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2001, 50: 1003-1011. 10.1016/S0360-3016(01)01547-4.CrossRefPubMed
10.
Vicini F, Kini VR, Chen P, Horwitz E, Gustafson G, Benitez P, Edmundson G, Goldstein N, McCarthy K, Martinez A: Irradiation of the tumor bed alone after lumpectomy in selected patients with early-stage breast cancer treated with breast conserving therapy. J Surg Oncol. 1999, 70: 33-40. 10.1002/(SICI)1096-9098(199901)70:1<33::AID-JSO6>3.0.CO;2-O.CrossRefPubMed
11.
Veronesi U, Orecchia R, Luini A, Gatti G, Intra M, Veronesi P, Gatzemeier W, Ciocca M, Tosi G, Ivaldi G, et al: Focalised intraoperative irradiation after conservative surgery for early stage breast cancer. The Breast. 2001, 10 (Suppl 3): 84-89.CrossRef
12.
Veronesi U, Orecchia R, Luini A, Gatti G, Intra M, Zurrida S, Ivaldi G, Tosi G, Ciocca M, Tosoni A, De Lucia F: A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers that are conservatively treated. Eur J Cancer. 2001, 37: 2178-2183. 10.1016/S0959-8049(01)00285-4.CrossRefPubMed
13.
Veronesi U, Paganelli G, Viale G, Galimberti V, Luini A, Zurrida S, Robertson C, Sacchini V, Veronesi P, Orvieto E, et al: Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst. 1999, 91: 368-373. 10.1093/jnci/91.4.368.CrossRefPubMed
14.
Intra M, Gatti G, Luini A, Galimberti V, Veronesi P, Zurrida S, Frasson A, Ciocca M, Orecchia R, Veronesi U: Surgical technique of intraoperative radiotherapy in conservative treatment of limited-stage breast cancer. Arch Surg. 2002, 137: 737-740. 10.1001/archsurg.137.6.737.CrossRefPubMed
15.
Cox JD, Stetx J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995, 31: 1341-1346. 10.1016/0360-3016(95)00060-C.CrossRefPubMed
16.
Tucker SS, Thames HD, Taylor JM: How well is the probability of tumor cure after fractionated irradiation described by Poisson statistics. Radiat Res. 1990, 124: 273-282.CrossRefPubMed
17.
The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer: Breast radiotherapy after breast-conserving surgery. CMAJ. 1998, 158 (Suppl 3): S35-42.
18.
Aref I, Cross P: Conservative surgery and radiation therapy for early stage breast cancer after previous mantle radiation for Hodgkin's disease. Br J Radiol. 2000, 73: 905-906.CrossRefPubMed
19.
Deutsch M, Gerszten K, Bloomer W, Avisar E: Lumpectomy and breast irradiation for breast cancer arising after previous radiotherapy for Hodgkin's disease. Am J Clin Oncol. 2001, 24: 33-34. 10.1097/00000421-200102000-00005.CrossRefPubMed
20.
Veronesi U, Marubini E, Mariani L, Galimberti V, Luini A, Veronesi P, Salvadori B, Zucali R: Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol. 2001, 12: 997-1003. 10.1023/A:1011136326943.CrossRefPubMed
21.
Dickler A, Kirk MC, Chu J, Nguyen C: The MammoSitetrade mark breast brachytherapy applicator: A review of technique and outcomes. Brachytherapy. 2005, 4: 130-136. 10.1016/j.brachy.2004.12.003.CrossRefPubMed
22.
Weed DW, Edmundson GK, Vicini FA, Chen PY, Martinez AA: Accelerated partial breast irradiation: A dosimetric comparison of three different techniques. Brachytherapy. 2005, 4: 121-129. 10.1016/j.brachy.2004.12.005.CrossRefPubMed
23.
Wallner P, Arthur D, Bartelink H, Connolly J, Edmundson G, Giuliano A, Goldstein N, Hevezi J, Julian T, Kuske R, et al: Workshop on partial breast irradiation: state of the art and the science, Bethesda, MD, December 8–10, 2002. J Natl Cancer Inst. 2004, 96: 175-184.CrossRefPubMed
24.
Intra M, Orecchia R, Veronesi U: Intraoperative radiotherapy: the debate continues. Lancet Oncol. 2004, 5: 340-10.1016/S1470-2045(04)01489-5.CrossRefPubMed
25.
Intra M, Leonardi MC, Gatti G, Vento AR, Ciocca M, Veronesi P, Bassani G, Dos Santos GR, Rodriguez J, Luini A, et al: Intraoperative radiotherapy during breast conserving surgery in patients previously treated with radiotherapy for Hodgkin's disease. Tumori. 2004, 90: 13-16.PubMed
Metadata
Title
A new option for early breast cancer patients previously irradiated for Hodgkin's disease: intraoperative radiotherapy with electrons (ELIOT)
Authors
Mattia Intra
Oreste Gentilini
Paolo Veronesi
Mario Ciocca
Alberto Luini
Roberta Lazzari
Javier Soteldo
Gabriel Farante
Roberto Orecchia
Umberto Veronesi
Publication date
01-10-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1310

Other articles of this Issue 5/2005

Breast Cancer Research 5/2005 Go to the issue

Research article

Expression of hypoxia-inducible factor 1 alpha and its downstream targets in fibroepithelial tumors of the breast

Commentary

Early stopping of clinical trials

Letter

CYP2D6 genotype and tamoxifen response

Research article

Obesity promotes 7,12-dimethylbenz(a)anthracene-induced mammary tumor development in female zucker rats

Research article

Percentage density, Wolfe's and Tabár's mammographic patterns: agreement and association with risk factors for breast cancer

Research article

Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits